redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
Published 1 year ago • 461 plays • Length 5:54Download video MP4
Download video MP3
Similar videos
-
3:04
monumental-1 update: talquetamab in r/r multiple myeloma
-
0:46
2-year follow-up of majestec-1: teclistamab in r/r multiple myeloma
-
1:59
a subgroup analysis of majestec-1: teclistamab in multiple myeloma with high-risk features
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
0:34
an update on the majestec-1 trial: the efficacy of less frequent dosing of teclistamab in rrmm
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
3:44
what should myeloma patients know about talquetamab?
-
17:55
talquetamab | therapies on the horizon
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
3:45
update on phase i trial of teclistamab in r/r myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
3:05
majestec-1: update on rp2d of teclistamab in r/r myeloma
-
3:12
updated results of the linker-mm1 trial: linvoseltamab in r/r multiple myeloma
-
2:49
trimm-2 update: talquetamab daratumumab in r/r multiple myeloma
-
1:04
majestec-1: teclistamab for myeloma
-
2:47
monumental-1: updated data on talquetamab in r/r myeloma
-
1:45
the value of teclistamab in r/r myeloma & strategies to mitigate toxicities